News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epi proColon® Receives the 2019 Excellence in Molecular Diagnostics Award

PDF Corporate LiveWire acknowledges the importance of a patient-accepted CRC detection method to effectively diagnose colorectal cancer. Berlin (Germany) and San Diego, CA (U.S.A.), May 9, 2019 –  Epigenomics AG is honored to have Epi proColon® recognized as the 2019 Excellence in Molecular Diagnostics award by Corporate LiveWire as part of the Innovation and Excellence […]

Read more

Epigenomics AG Reports 2019 First Quarter Financial Results

PDF Berlin (Germany) und San Diego, CA (U.S.A.), May 8, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced the financial results (according to IFRS; unaudited) for the first quarter of the FY 2019. KEY HIGHLIGHTS Financial Total revenue increased to EUR 331 thousand (Q1 2018: EUR 309 thousand) primarily due to […]

Read more

CMS accepts Epigenomics’ application for NCD review

PDF Berlin (Germany) and San Diego, CA (U.S.A.), May 3, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) has accepted the company’s application for a National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal cancer screening. The […]

Read more

Epigenomics AG Reports Results for Financial Year 2018

PDF Berlin (Germany) und San Diego, CA (U.S.A.), March 27, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced the financial results (according to IFRS) for the year ended December 31, 2018. KEY HIGHLIGHTS Financial – Total revenue of EUR 1.5 million and EBITDA (before share-based payment expenses) of EUR -11.4 million (compared […]

Read more

U.S. Representatives Payne and Marchant Introduce Bi-Partisan Colorectal Cancer Detection Bill

PDF Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests Berlin (Germany) and San Diego, CA (U.S.A.), March 15, 2019 – Representatives Donald Payne, Jr (D-NJ) and Kenny Marchant (R-TX) today introduced the ”Donald Payne Sr. Colorectal Cancer Detection Act” (HR 1765) to the United States House […]

Read more

Epigenomics AG Announces Positive Results from Microsimulation Model

PDF Berlin (Germany) and San Diego, CA (U.S.A.), January 7, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that a microsimulation model has been completed by external academic experts demonstrating positive results for the Epi proColon® blood test. The manuscript is being finalized and will be submitted for publication soon. Epigenomics will discuss […]

Read more